John McCorvy, PhD, Assistant Professor in the Department of Cell Biology, Neurobiology, and Anatomy at the Medical College of Wisconsin (MCW); Adam Halberstadt, PhD, Professor of Psychiatry at the University of California San Diego (UCSD) and Director of the UCSD Center for Psychedelic Research; and Kevin Murnane, PhD, Associate Professor of Pharmacology, Toxicology, and Neuroscience and Director of Basic Science Research for the Louisiana Addiction Research Center at LSU Health Shreveport, were recently awarded a five-year, $2.4 million research grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to uncover critical insights into how psychedelics could be used as a therapeutic to treat methamphetamine addiction.
PharmAla Biotech Holdings Inc. – Cortexa Makes First Drug Order for Australian Commercial Market | Psychedelic Invest
PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including
July 7, 2023